Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
Nivolumab plus ipilimumab demonstrated antitumor activity among patients with either primary or secondary angiosarcoma, according to phase 2 data.
CPI-006, a B-cell activating antibody which is under development as an anticancer therapy, showed early efficacy as a potential treatment for COVID-19.
Pretreatment with G-CSF prior to receiving an autologous DC-based vaccine resulted in worse outcomes compared with no G-CSF, according to results of a phase 2b study.
The PD-1 inhibitor retifanlimab showed antitumor activity with a tolerable safety profile among patients with MSI-H/dMMR endometrial cancer.
Antibiotic use prior to ICI treatment may reduce ICI efficacy and result in worse survival outcomes among patients with cancer, in a retrospective study.
A DLL3-targeted BiTE demonstrated antitumor activity — but high rates of CRS — among patients with previously-treated SCLC.
Extracellular vesicles carrying PD-L1 as cargo may function as a predictive biomarker for immunotherapy response in NSCLC.
Neoadjuvant CMP-001 plus nivolumab demonstrated antitumor activity and upregulated the intratumor immune response in patients with stage III melanoma.
Neoadjuvant treatment with chemotherapy plus nivolumab resulted in a greater frequency of NSCLC downstaging compared with chemotherapy or ICI treatment alone.
A vaccine consisting of autologous dendritic cells exposed to tumor antigens was well tolerated and showed clinical benefit among patients with glioblastoma.
A neoantigen vaccine administered in the adjuvant setting to patients with different cancer types was well tolerated and generated a T-cell response .
A study evaluated characteristics of pseudoprogression among patients with cervical cancer treated with ICIs.
Use of dexamethasone was associated with shorter survival in those with glioblastoma treated with a PD-1/PD-L1 inhibitor.
BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.
Bemcentinib, an AXL inhibitor, was tolerable and demonstrated antitumor activity in combination with pembrolizumab in AXL-positive, relapsed NSCLC.
NKTR-262 enhances antigen presentation and demonstrated early efficacy and a tolerable safety profile in combination with bempegaldesleukin in pretreated advanced solid tumors.
NIZ985, a heterodimer of IL-15 and IL-15α, showed antitumor activity when combined with spartalizumab among patients with pretreated, advanced solid tumors, in a phase 1 study.